Literature DB >> 29068484

The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.

A Q Reuwer1, M Heron1, D van der Dussen2, T Schneider-Hohendorf3, J L Murk1.   

Abstract

In natalizumab-treated patients without previous immunosuppressive treatment, the JCV antibody index is used to stratify PML risk. A high index value indicates that the risk to develop PML is significantly elevated, although probably about 99% of patients with this index value will not develop PML. This minireview aimed to provide an overview of the basic virology and immunology relevant to understanding JCV infections in MS patients, with a focus on what is presently known about antibodies to JCV and how they could be of use to predict and diagnose PML.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  JC virus; adaptive immune response; antibodies, antibody index; neuro-immune surveillance; progressive multifocal leukoencephalopathy

Mesh：

Substances：

Year:  2017        PMID： 29068484     DOI： 10.1111/ane.12840

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


  5 in total

1.  Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.

Authors:  Belén Rodríguez de Castro; Cristina Martinez-Múgica Barbosa; Aitor Ayastuy Ruiz; Beatriz Fernández González
Journal:  Eur J Hosp Pharm       Date:  2019-10-16

2.  Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.

Authors:  Mitsuru Watanabe; Yuri Nakamura; Noriko Isobe; Masami Tanaka; Ayako Sakoda; Fumie Hayashi; Yuji Kawano; Ryo Yamasaki; Takuya Matsushita; Jun-Ichi Kira
Journal:  J Neuroinflammation       Date:  2020-07-09       Impact factor: 8.322

3.  Training physicians in providing complex information to patients with multiple sclerosis: a randomised controlled trial.

Authors:  Jenny M Nordfalk; Trygve Holmøy; Owen Thomas; Magne Nylenna; Pal Gulbrandsen
Journal:  BMJ Open       Date:  2022-03-15       Impact factor: 2.692

4.  Seroprevalence of fourteen human polyomaviruses determined in blood donors.

Authors:  Sergio Kamminga; Els van der Meijden; Mariet C W Feltkamp; Hans L Zaaijer
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

5.  JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies.

Authors:  Robert Bonek; Wojciech Guenter; Robert Jałowiński; Anna Karbicka; Anna Litwin; Maciej Maciejowski; Radosław Zajdel; Karolina Zajdel; Veronique Petit; Konrad Rejdak
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.